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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.026Corneal scarring, whether caused by trauma, laser refractive surgery, or infection, remains a signiﬁcant
problem for humans. Certain ligands for peroxisome proliferator-activated receptor gamma (PPARg)
have shown promise as antiscarring agents in a variety of body tissues. In the cornea, their relative
effectiveness and mechanisms of action are still poorly understood. Here, we contrasted the antiﬁbrotic
effects of three different PPARg ligands (15-deoxy-D12,14-prostaglandin J2, troglitazone, and rosi-
glitazone) in cat corneal ﬁbroblasts. Western blot analyses revealed that all three compounds reduced
transforming growth factor (TGF)-b1edriven myoﬁbroblast differentiation and up-regulation of
a-smooth muscle actin, type I collagen, and ﬁbronectin expression. Because these effects were inde-
pendent of PPARg, we ascertained whether they occurred by altering phosphorylation of Smads 2/3,
p38 mitogeneactivated protein kinase, stress-activated protein kinase, protein kinase B, extracellular
signal-regulated kinase, and/or myosin light chain 2. Only p38 mitogeneactivated protein kinase
phosphorylation was signiﬁcantly inhibited by all three PPARg ligands. Finally, we tested the anti-
ﬁbrotic potential of troglitazone in a cat model of photorefractive keratectomyeinduced corneal injury.
Topical application of troglitazone signiﬁcantly reduced a-smooth muscle actin expression and haze in
the stromal ablation zone. Thus, the PPARg ligands tested here showed great promise as antiﬁbrotics,
both in vitro and in vivo. Our results also provided new evidence for the signaling pathways that may
underlie these antiﬁbrotic actions in corneal ﬁbroblasts. (Am J Pathol 2014, 184: 1429e1445; http://
dx.doi.org/10.1016/j.ajpath.2014.01.026)Supported by the NIH (grants EY015836, EY017123, HL75432, K23
EY019353, and core grant P30 EY001319 to the Center for Visual Sci-
ence), an unrestricted grant to the Department of Ophthalmology (Uni-
versity of Rochester) from the Research to Prevent Blindness Foundation,
and the Lew R. Wasserman Merit Award from the Research to Prevent
Blindness Foundation (K.R.H.).
Disclosures: None declared.Maintaining the transparency and regular shape of the
cornea are essential for normal vision. After corneal dam-
age, stromal keratocytes that survive the injury become
exposed to multiple wound healing mediators, including
transforming growth factor (TGF)-b, the strongest known
proﬁbrotic agent.1,2 As a result, corneal keratocytes prolif-
erate, migrate, transform into ﬁbroblasts,3 and ultimately
transform into myoﬁbroblasts.4 In some ways, myoﬁbro-
blasts are well suited to restore corneal integrity after injury
because they can contract wounds and secrete extracellular
matrix components.5 However, persistent myoﬁbroblast
activity also decreases corneal transparency,6 and by con-
tracting the cornea, they induce certain higher-order, optical
aberrations, which negatively affect optical quality.7
TGF-b initiates proﬁbrotic changes in cell behavior by
binding TGF-b receptors on the cell surface, causingstigative Pathology.
.phosphorylation of several cytoplasmic substrates, including
members of the Smad family. Smads 2 and 3 each form
heterodimeric complexes with Smad 4, which translocates
to the nucleus and activates transcription of select target
genes.8 However, TGF-b receptor binding also activates
non-Smad intracellular signaling pathways, such as TGF-
beassociated kinase 1, extracellular signaleregulated
kinase (Erk), p38 mitogeneactivated protein kinase
(MAPK), Rho-associated protein kinase (ROCK), and
Jeon et alprotein kinase B/AKT.9 Because activation of TGF-b ap-
pears to be a central regulator of events during wound
healing,10 developing strategies to prevent TGF-berelated
activities seems an appealing antiscarring approach. Con-
ﬁrming this notion, application of antibodies against TGF-b
to the ocular surface reduced corneal reﬂectivity (haze) and
ﬁbrosis after photorefractive keratectomy (PRK) in rabbits11
and cats.7 However, epithelial healing was also slowed, and
myoﬁbroblast differentiation, stromal regrowth, haze, and
increases in higher-order optical aberrations were not
completely eliminated.7,11
Clinically, the most commonly used pharmacologic
agents for the modulation of corneal wound healing after
PRK in humans are mitomycin C12 and steroids, such as
prednisolone acetate.13 Although short- and long-term
adverse effects of mitomycin C have been reported,12,14
long-term use of corticosteroids can depress immune re-
actions (predisposing individuals to infections), increase
intraocular pressure (which can lead to permanent vision
loss), and cause cataract formation (further disrupting opti-
cal clarity).15 Thus, there is a need for better ways of
treating corneal ﬁbrosis, without the adverse effects inherent
in mitomycin C or steroids and without the concern of
applying antieTGF-b antibodies to the eye.
In this context, our group and others have found several
ligands of PPARg to be effective corneal antiﬁbrotics
in vitro16e18 and, most recently, in vivo.19 PPARg is a
transcription factor belonging to a nuclear receptor super-
family that regulates important cellular functions, including
metabolism, adipogenesis, proliferation, and differentiation,
as well as inﬂammatory responses.20 A signiﬁcant body of
mostly cell culture data suggests that PPARg ligands can act
as antiﬁbrotics in several body tissues, including lung,21
skin,22 kidneys,23 and cornea.16e18 Interestingly, in
cultured human corneal ﬁbroblasts, the electrophilic ligands
CDDO and 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2)
appear to have stronger antiﬁbrotic actions than non-
electrophilic ligands, such as rosiglitazone.16 Yet, in vivo,
rosiglitazone was highly effective at controlling corneal
ﬁbrosis after PRK in the cat eye, without any apparent
adverse effects or toxicity.19
Our goal was to examine the antiﬁbrotic properties of
three different PPARg ligands (troglitazone, rosiglitazone,
and 15d-PGJ2) in cultured cat corneal ﬁbroblasts. Under-
standing the mechanisms of action of different PPARg
ligands seems critical for estimating both their safety and
efﬁcacy in the context of corneal wound healing. Thus, we
asked the following: i) what is the relative time course of
expression of a-smooth muscle actin (a-SMA), collagen 1
(COL1), and ﬁbronectin (FN) after TGF-b1 stimulation in
cat corneal ﬁbroblasts? ii) Are different classes of PPARg
ligands (electrophilic versus nonelectrophilic) equally
effective as corneal antiﬁbrotics in vitro? In particular, were
prior reports of ineffectiveness of some nonelectrophilic
ligands due to tissue, species differences, or suboptimal
dosing? iii) When used at optimal doses, do all three1430PPARg ligands decrease expression of a-SMA, COL1, and
FN at the same rate and to the same extent? iv) What
signaling pathways do PPARg ligands inﬂuence in corneal
ﬁbroblasts, and are they important for mediating their
observed antiﬁbrotic effects?
Materials and Methods
All animal procedures were conducted according to the
guidelines of the University of Rochester Committee on
Animal Research, the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research, and the NIH Guide for the
Care and Use of Laboratory Animals.
Isolation of Primary Cat Corneal Fibroblasts and
Culture Conditions
Primary feline corneal ﬁbroblasts were isolated from fresh,
young, adult, domestic, short-hair cats (Felis cattus) by
double collagenase digestion, as previously described.19
Mitogen-poor horse serum (HS) was used here instead of
fetal bovine serum (FBS) in an attempt to keep cells in a
more quiescent state. Prior work has shown that cells
cultured in HS retained their keratocyte morphologic fea-
tures longer and secreted highly sulfated forms of keratin
sulfate proteoglycan, a keratocyte marker.3,24,25 In addition,
Chen et al26 conﬁrmed that keratocan and CD34, both
keratocyte markers, were expressed in bovine corneal cell
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)/
10% HS, whereas these molecules were not expressed in
cells cultured in DMEM/10% FBS. Part of the reason why
FBS might cause cultured cells to lose their keratocyte
phenotype is that it contains high levels of latent TGF-b,27
which can be activated by cell-associated plasmin28 during
the cell culture process. Passage 6 to 7 ﬁbroblasts were used
for all experiments and kept in 1% HS-DMEM/nutrient
mixture F-12 (F12) for 1 day to promote cellular quies-
cence after attachment.
Immunocytochemistry
Corneal ﬁbroblasts were seeded at a density of 1  104 cell/
well in Lab-Tek II Chamber slides in 5% HS-DMEM/F12.
Cells were then pretreated with optimal doses of the three
PPARg ligands (15 mmol/L troglitazone, 75 mmol/L rosi-
glitazone, and 5 mmol/L 15d-PGJ2) in 1% HS-DMEM/F12
for 30 minutes. TGF-b1 (1 ng/mL) was then added to the
medium, and the cells were incubated for 3 days without
any medium changes. For immunoﬂuorescent staining, the
chamber slides were rinsed with DMEM/F12 without serum
and ﬁxed with 4% paraformaldehyde (Electron Microscopy
Sciences, Hatﬁeld, PA) in 1 PBS on ice for 15 minutes,
followed by permeabilization with acetone (J. T. Baker,
New York, NY) at 20C for 10 minutes. Nonspeciﬁc
binding was blocked with 3% normal goat serum (Jacksonajp.amjpathol.org - The American Journal of Pathology
PPARg Ligands and Corneal FibroblastsImmunoResearch, West Grove, PA) and 0.025% Triton X-
100 (Sigma-Aldrich, St. Louis, MO) in 1 PBS for 30
minutes. Primary antibodies were then applied to the slides.
They included polyclonal rabbit anti-mouse FN (1:150,
AB2033, Millipore, Billerica, MA) and monoclonal mouse
anti-human a-SMA (1:400, clone 1A4, ThermoScientiﬁc,
Waltham, MA). The slides were incubated at 4C overnight.
After washing off the primary antibodies with 1 PBS, the
slides were incubated with secondary goat anti-rabbit IgG
conjugated to Alexa Fluor 488 (1:500, A11008, Invitrogen,
Carlsbad, CA) and goat anti-mouse IgG conjugated to Alexa
Fluor 555 (1:300, A21422, Invitrogen) for 2 hours at room
temperature. Slides were coverslipped using Vectashield
plus DAPI (Vector Laboratories, Burlingame, CA). Finally,
the triple-labeled cell cultures were imaged using an
Olympus AX70 ﬂuorescence microscope, and photomicro-
graphs were collected via a high-resolution video camera
interfaced with a personal computer running the ImagePro
software (MediaCybernetics, Bethesda, MD).
Effect of PPARg Ligands on TGF-b1eInduced
Expression of a-SMA, COL1, and FN in Cultured Corneal
Fibroblasts
A density of 2.5 104 to 7.5 104 cells/well in 6-well plates
was used. The cells were then pretreated with each of the three
PPARg ligands of interest [troglitazone (Cayman Chemical
Company, Ann Arbor, MI), rosiglitazone (Cayman Chemical
Company), or 15d-PGJ2 (Enzo, Plymouth Meeting, PA)] in
1%HS-DMEM/F12medium (rather than serum-free medium)
for 30 minutes to avoid cytotoxicity on addition of 15d-PGJ2.
One nanogram per milliliter of recombinant human TGF-b1
(R&D Systems Inc., Minneapolis, MN) was then added to the
medium, and the cells were incubated for 1, 2, or 3 days
without any medium changes. Western blot analysis was then
performed as previously described.19
PPARg Dependency of Antiﬁbrotic Effects in Cultured
Corneal Fibroblasts
To test whether the observed antiﬁbrotic effects of trogli-
tazone, rosiglitazone, and 15d-PGJ2 were PPARg depen-
dent or independent, we used both a pharmacologic and a
genetic approach that blocked PPARg function in our
cultured corneal ﬁbroblasts. For the pharmacologic
approach, cat corneal ﬁbroblasts were seeded and kept
quiescent for 1 day as described above. Cells were then
pretreated with 0.5 or 1 mmol/L of the synthetic PPARg
antagonist GW9662 (Cayman Chemical Company) for 1
hour, after which optimal doses of PPARg ligands were
added for 30 minutes before the addition of TGF-b to the
medium. The cells were incubated for 3 days before har-
vesting and evaluation by Western blot analysis.
To verify the effectiveness of GW9662 (as well as of the
genetic approach described below) at blocking PPARg
function in cat cells, we ran a separate, control experiment inThe American Journal of Pathology - ajp.amjpathol.orgwhich cat orbital ﬁbroblasts were isolated. This class of cells
is closely related to corneal keratocytes but is able to syn-
thesize fat in a PPARg-dependent manner.29 Approximately
500 to 1000 mg of feline orbital fat was rinsed three times in
PBS and cut into approximately 2- to 4-mm3 pieces. Sam-
ples were then digested in 5 mL of HBSS containing
collagenase (200 U/mL) for 90 minutes at 37C, mixing
every 10 minutes. The reaction was stopped with the addi-
tion of DMEM/10% FBS, and cells were collected by
centrifugation (1000  g for 10 minutes). They were then
plated and cultured in DMEM/10% FBS in 10-cm2 dishes to
establish ﬁbroblast strains. After culture expansion, passage
4 orbital ﬁbroblasts (5000 cells/cm2) were plated in 24-well
plates (Corning, Corning, NY) and grown in DMEM/5%
FBS to conﬂuence. The medium was then replaced with
vehicle [dimethylsulfoxide (DMSO)] or 5 mmol/L 15d-PGJ2
(Cayman Chemical Company) and 1 mg/mL of insulin
(Sigma-Aldrich) to stimulate adipogenesis according to
standard protocols.30 A fraction of the wells also received 1
mmol/L GW9662 alone. The culture medium was replaced
every 2 days for a total of 8 days of treatment. To wells
receiving GW9662, 1 mmol/L fresh GW9662 was added
every day of the experiment. On the eighth day, adipo-
genesis was measured using the AdipoRed reagent (Cayman
Chemical Company), which measures neutral lipid accu-
mulation inside the cells. Brieﬂy, culture medium was
aspirated and samples were rinsed in room temperature
PBS. Samples were incubated with the AdipoRed reagent
for 10 minutes at room temperature in the dark to allow for
lipid-AdipoRed binding. The plates were then excited at 485
nm in a Varioskan Flash Multimode Reader (Thermo-
Scientiﬁc), and ﬂuorescence was quantiﬁed at 572 nm.
Lentiviral (Lv) transduction of a dominant negative (DN)
PPARg construct was used as a second method to test
whether PPARg ligands function in a PPARg-independent
manner. Green ﬂuorescent protein (GFP)-Lv and PPARg-
DN-Lv (which encoded ﬂag-tagged PPARg1 L466A/
E469A) were produced as previously described.31 Feline
corneal ﬁbroblasts or feline orbital ﬁbroblasts were plated as
above and infected with GFP-Lv or PPARg-DN-Lv at a
multiplicity of infection of 10 for 24 hours. The medium
was replaced and infected cells were treated as above to test
PPARg dependency in corneal ﬁbroblasts with PPARg li-
gands and TGF-b treatment and in orbital ﬁbroblasts with
adipogenic treatment. Myoﬁbroblast formation and adipo-
genesis were measured by Western blot analysis and the
Adipored assay, respectively, as described above.
Effect of PPARg Ligands on TGF-b1eInduced
Phosphorylation of Smads 2/3 in Cultured Corneal
Fibroblasts
To study whether PPARg ligands used in the present ex-
periments affected phosphorylation of Smads 2/3, corneal
ﬁbroblasts were seeded and incubated under a low-serum
condition as mentioned earlier. Pretreatment with PPARg1431
Jeon et alligands for 30 minutes was followed by addition of 1 ng/mL
of TGF-b1 to the medium. Cells were incubated for 1 to
6 hours before sampling for Western blot analysis. The
primary antibodies used in these Western blots included
antiphosphorylated Smad 2 (Ser465/467; Millipore), anti-
phosphorylated Smad 3 (Ser423/425; Millipore), and total
anti-Smads 2/3 (D7G7; Cell Signaling, Beverly, MA).
Effect of PPARg Ligands on TGF-b1eInduced Nuclear
Translocation of Smads 2/3 in Cultured Corneal
Fibroblasts
After TGF-b1 stimulation, phosphorylated Smads 2/3 form
complexes with Smad 4 and translocate to the nucleus,
where they regulate transcription of target genes.32 After
assessing the effect of PPARg ligands on phosphorylation
of Smads 2/3, it was also important to assess whether
PPARg ligands affected the translocation of p-Smads 2/3
into the nucleus. Thus, 1.5  106 cells per 10-cm dishes
were pretreated with 15 mmol/L troglitazone. Cells were
then treated with TGF-b1 for 1 hour before being washed
with 1 Dulbecco’s PBS containing 1 mmol/L sodium
orthovanadate (NO3VO4; Sigma-Aldrich). We then added
1 mL of Trypsin-EDTA (0.25%; Gibco BRL, Gaithersburg,
MD) and collected and centrifuged at 400  g for 5 mi-
nutes; the pellet was then rinsed once or twice in ice-cold
1 Dulbecco’s PBS containing 1 mmol/L NO3VO4. The
pellet was gently resuspended in 200 mL of lysis buffer B
(10 mmol/L Tris, pH 8.4, 140 mmol/L NaCl, 1.5 mmol/L
MgCl2, 1 mmol/L dithiothreitol, 0.1% NP-40, 0.5 mmol/L
phenylmethylsulfonyl ﬂuoride, 1 mmol/L NO3VO4, and
complete protease inhibitor) without 0.1% NP-40. Cellular
morphology was checked under a microscope to verify that
the cells were rounding up without aggregating, at which
stage 0.05% NP-40 was added while slowly vortexing for
10 to 15 seconds. More than 90% of cells ruptured as a
result. The broken cell suspension was incubated on ice for
5 minutes before lysates were pelleted by centrifugation at
15,350  g for 20 seconds at 4C. After centrifugation, the
supernatant was saved as the cytoplasmic fraction. The
pellet fractions were rinsed once in lysis buffer B. Regular
cell lysis buffer was then added and kept on ice for 10
minutes. Finally, the lysates were centrifuged at 15,350  g
for 10 minutes, and the supernatants were now saved as the
nuclear fractions. To check for cross-contamination between
cytoplasmic and nuclear fractions, antieb-tubulin was used
as a cytoplasmic marker, and puriﬁed mouse anti-SC35 (BD
Pharmingen, San Jose, CA) was used as a nuclear marker.
Effect of TGF-b1 Stimulation on Phosphorylation of
Downstream Signaling Molecules in Cat Corneal
Fibroblasts
To assess the involvement of different non-Smad intracellular
signaling pathways in TGF-beinduced responses, ﬁbroblasts
were cultured as described for the phosphorylated Smads 2/31432experiment. Cells were treated with 1 ng/mL of TGF-b1 and
incubated for times ranging from 10 minutes to 24 hours
before sampling to run Western blots. The antibodies for
candidate kinases tested included anti-phosphorylated p38
MAPK (Thr180/Tyr182), anti-phosphorylated Akt (Ser473),
anti-phosphorylated p44/42 MAPK (Erk1/2; Thr202/Tyr204),
anti-phosphorylated SAPK/JNK (Thr183/Tyr185), and anti-
phosphorylated MLC2 (Thr18/Ser19). All antibodies were
purchased from Cell Signaling Technology. We evaluated the
expression of phosphorylated p38 relative to total levels of p38
and of phosphorylated JNK, phosphorylated Akt, phosphor-
ylated ERK, and phosphorylated MLC2 relative to b-tubulin
via densitometric measurements.
Effect of Kinase Inhibitors on TGF-b1eInduced
Expression of a-SMA, COL1, and FN in Cultured Corneal
Fibroblasts
Our next goal was to identify the intracellular pathways most
strongly activated by TGF-b1 stimulation in cat corneal ﬁ-
broblasts under our particular cell culture conditions. We
therefore used several small-molecule kinase inhibitors to
block the major, known, endogenous, proﬁbrotic protein ki-
nases9 and monitored the resultant molecular changes. Spe-
ciﬁcally, we used a TGF-b receptor 1 inhibitor (SB431542),33
a Rho-associated kinase (Rho-kinase) inhibitor (H-1152),34
an ERK inhibitor (U0126),35 a JNK inhibitor (JNK inhibitor
III and SP600125),36 a p38 MAPK inhibitor (SB203580),37
and an AKT inhibitor (LY294002).38 All inhibitors were
obtained from Calbiochem (San Diego, CA). Fibroblasts
were seeded at a density of 1  105 cells/well in 6-well
plates according to protocols outlined above. Dose depen-
dence for each kinase inhibitor was ﬁrst determined by
pretreating cells in DMEM/F12/1%HS for 30minutes, after
which 1 ng/mL of TGF-b1 was added to the medium, and
the cells were incubated for 3 days. Western blots were
performed to assess the expression of a-SMA, COL1, and
FN as described earlier.
Effect of PPARg Ligands on TGF-b1eInduced p38
MAPK Signaling in Cultured Corneal Fibroblasts
To assess whether the p38 MAPK signaling pathway might
be a speciﬁc target of our three PPARg ligands of interest,
ﬁbroblasts were seeded at a density of 2.5 104 to 7.5 104
cells per well in 6-well plates and treated as described earlier.
The cells were incubated for 2 days without any medium
changes. The expression of phosphorylated p38 MAPK
relative to total levels of p38 was then evaluated.
Antiﬁbrotic Effects of Troglitazone in Vivo
To assess whether PPARg ligands could inhibit corneal
ﬁbrosis in vivo, as well as in vitro, we used PRK to induce
identical corneal wounds in the eyes of adult, domestic,
short-hair cats, using well-established protocols.39 In brief, aajp.amjpathol.org - The American Journal of Pathology
PPARg Ligands and Corneal Fibroblasts10D, conventional PRK was performed over a 6-mm
optical zone with a central ablation depth of 168 mm (Pla-
noscan 4.14; Bausch & Lomb, Rochester, NY). All pro-
cedures were performed under topical (0.5% proparacaine;
Falcon, Fort Worth, TX) and surgical anesthesia (5
mg$kg1 ketamine, 0.04 mg$kg1 medetomidine hydro-
chloride), using a Technolas 217 laser (Bausch & Lomb).
Immediately after PRK, drugs were applied to each eye and
held in place on the stromal bed using a saturated, sterile,
gelatin sponge (Surgifoam; Ethicon, Piscataway, NJ) for 2
minutes. Each eye then received a drop of antibiotic solution
(neomycin, polymyxin B sulfate, gramicidin ophthalmic
solution USP; Bausch & Lomb).
A ﬁrst group of three animals was used to establish the
optimal dose of troglitazone for this application. For the
following 2 weeks, one eye of each cat received 1 drop (50
mL) of troglitazone (Cayman Chemical Company) diluted in
vehicle solution consisting of 10% DMSO in Celluvisc
(RefreshCelluvisc; Allergan, Irvine, CA) twice per day and
one drop of antibiotic daily, whereas the other eye received
vehicle solution (10% DMSO in Celluvisc) followed by one
drop of antibiotic daily. Three different concentrations of
troglitazone were tested: 1 mmol/L, 10 mmol/L, and 100
mmol/L. Cats were monitored for the development of haze via
direct observation and once per week via OCT imaging, as
previously described.39,40 In brief, OCT imaging sessions
required that the animals receive general anesthesia, as for
PRK. Lubricating gel (GenTeal; Novartis, East Hanover, NJ)
was applied to each eye. The head was stabilized, and the
OCT was centered on the pupil. Videos of the central 10 mm
of each cornea were collected at eight frames per second.
Once the optimal dose of troglitazone application in vivo
was identiﬁed (10 mmol/L), an additional nine cats under-
went identical, bilateral PRK to assess the optical and his-
tologic effect of troglitazone treatment in a larger cohort and
for a longer period (12 weeks postoperatively). PRK pro-
cedures and postoperative drug administration were as
described above, except that 10 mmol/L troglitazone was the
only dose of this drug used. Troglitazone was administered
to one eye of each cat, whereas the other eye received
vehicle for 2 weeks after PRK. OCT imaging was performed
preoperatively, then every 2 weeks after PRK for 12 weeks.
Measurement of backscatter reﬂectivity, which can be used
as an index of haze in the anterior cornea, was performed as
follows: four sampling lines were drawn in each of 10 corneal
images per eye per time point. Of the four sampling lines, two
were on each side of the central pixel of each image, starting
approximately 1 mm from the corneal center, and with each
pair of lines further separated by approximately 1 mm. A
pixel intensity proﬁle from epithelium to endothelium was
generated for each line in ImageJ version 64 (National In-
stitutes of Health, Bethesda, MD) before averaging across all
four lines. To compensate for ﬂuctuations in laser strength,
mean proﬁles were normalized to the mean pixel intensity in
a background region (exterior to the cornea) in each image.
The region of the curve corresponding to the stroma was thenThe American Journal of Pathology - ajp.amjpathol.orgdivided into thirds, and we computed the mean, normalized
pixel intensity over the anterior and posterior thirds in each
image. These pixel intensity values were then averaged
across 10 images per eye per time point.
At 2 and 4 weeks after PRK (and 2 weeks after stopping
administration of troglitazone or vehicle to the eyes), four cats
were euthanized so that the corneas could be excised and
processed for histologic analysis. Excised corneas were drop-
ﬁxed in 1% paraformaldehyde/0.1 mol/L PBS, pH 7.4, for 10
minutes. They were then transferred to 30% sucrose/0.1 mol/
L PBS and stored at 4C for 2 days. After embedding into
blocks (Tissue Tek O.C.T. Compound; Sakura Finetek,
Zoeterwoude, Netherlands), serial cross sections (20 mm
thick) were cut on a cryostat (2800 Frigocut E; Leica,
Nußloch, Germany), mounted on microscope slides, and
stored in a 20C freezer until ready to stain. Slides con-
taining three corneal sections each were air dried and rinsed in
0.01 mol/L PBS. Two sections per slide were incubated
overnight at 4Cwith 2 mg$mL1mousemonoclonal antiea-
SMA antibody (clone 1A4; Sigma-Aldrich). The third section
was incubatedwith 0.1mol/L PBS as a negative control. After
washing off the primary antibody with 0.01 mol/L PBS,
sections were reacted with anti-mouse IgG tagged with
AlexaFluor 488 (2 mg$mL1; Molecular Probes, Eugene,
OR), followed by 0.1 mg$mL1 propidium iodide (Invi-
trogen) to label cell nuclei. Double-labeled sections were
imaged using an Olympus AX70 ﬂuorescence microscope,
and photomicrographs were collected via a high-resolution
video camera interfaced with a personal computer running
ImagePro software version 5.0 (MediaCybernetics).
Statistical Analysis
When three or more groups were compared, intergroup
differences were tested with either a two-way analysis of
variance or a one-way analysis of variance as applicable.
When only two groups were compared, a two-sided Stu-
dent’s t-test was performed. A probability of error of
P < 0.05 was considered statistically signiﬁcant unless a
Bonferroni correction was applied for multiple comparisons,
in which case signiﬁcant P values were indicated in the text.
All statistical tests were performed using the SPSS software
package version 20.0.0 (SPSS Inc., Chicago, IL).
Results
PPARg Ligands Decrease TGF-b1eInduced Expression
of a-SMA, COL1, and FN
In the absence of TGF-b1 stimulation, basal levels of a-SMA
expression were close to zero in cat corneal ﬁbroblasts,
whether at 1, 2, or 3 days in culture (Figures 1, 2 and 3).
However, the basal levels of COL1 and FN were distinctly
above zero, conﬁrming that these two extracellular matrix
components were constitutively synthesized at low levels by
corneal ﬁbroblasts in vitro.1433
Figure 1 Antiﬁbrotic effects of troglitazone on feline corneal ﬁbro-
blasts. A: Representative Western blots show protein levels for ﬁbronectin
(FN), collagen type I (COL1), and a-SMA, with b-tubulin levels assayed as a
loading control. b-tubulin levels were stable throughout. B: Plots of rela-
tive expression of FN, COL1, and a-SMA normalized to densitometric values
obtained in cells stimulated with only 1 ng/mL TGF-b1 for each culture day
sampled. Data are means  SD averaged for three experiments.
*P < 0.0125 (four comparisons), yP < 0.0167 (three comparisons) by
Bonferroni-corrected Student’s t-test relative to TGF-b1eonly condition (df
Z 4 for all tests).
Jeon et alAfter 1 day of culture (Figure 1A), troglitazone appeared to
have no effect on the expression of FN and COL1, whereas a-
SMA expression did not sufﬁciently increase to assay any
inhibitory effects. After 2 days in culture, troglitazone still
exerted no signiﬁcant effect on a-SMA or FN expression, but it
exerted a signiﬁcant dampening of COL1 expression at the two
highest doses of 10 mmol/L and 15 mmol/L. After 3 days of
culture, 15 mmol/L of troglitazone administered together with
TGF-b clearly inhibited the expression of all three proﬁbrotic
proteins relative to levels expressed after incubation with TGF-
b alone for 3 days (Figure 1B).
Although some effect could be observed at lower doses,
rosiglitazone clearly inhibited the expression of all three
TGF-b1einduced proﬁbrotic proteins at 75 mmol/L,
whereas b-tubulin levels remained stable (Figure 2A). After
1 day of culture, rosiglitazone appeared to have no statisti-
cally signiﬁcant effect on the expression of COL1, whereas1434a-SMA expression did not sufﬁciently increase at this time
point to assay the effect of rosiglitazone. Only FN expres-
sion was signiﬁcantly decreased by 75 mmol/L rosiglitazone.
After 2 days in culture, 75 mmol/L rosiglitazone signiﬁ-
cantly decreased expression of a-SMA and COL1 relative to
the TGF-beonly conditions. After 3 days of culture with 75
mmol/L of rosiglitazone and TGF-b, expression of a-SMA
and FN decreased signiﬁcantly relative to the TGF-beonly
condition (Figure 2B).
After 1 day of culture, 15d-PGJ2 had a statistically sig-
niﬁcant effect on the expression of COL1 and FN, whereas
a-SMA expression did not sufﬁciently increase at this time
point to assess any inhibitory effects. After 2 and 3 days in
culture, the quantitative analysis conﬁrmed that all doses
used signiﬁcantly and completely prevented the induction of
a-SMA expression. However, for COL1 and FN only the
highest dose of 15d-PGJ2 (5 mmol/L) was able to signiﬁ-
cantly decrease protein expression relative to the TGF-
beonly condition (Figure 3, A and B).
In summary, after 1 day of treatment with TGF-b1, a-SMA,
COL1, and FN levels increased by four- to ﬁvefold relative to
vehicle-treated control cultures (Figure 4A). After 2 and 3 days
of treatment with TGF-b1, although the expression of all three
molecules increased even higher relative to the vehicle-treated
condition, the effect of TGF-b on a-SMA appeared greater
than on COL1 and FN (Figure 4A), with means  SEM
Western blot band intensities for a-SMA of 23 2.6-fold and
a 60- 13.3-fold increase relative to baseline at 2 and 3 days in
culture, respectively. In contrast, COL1 levels increased by
means  SEM of 14  3.7-fold and 11  2.7-fold respec-
tively, and FN levels increased by 12 1.9-fold and 25 6.0-
fold, respectively after 2 and 3 days in culture. An analysis of
variance probing the effect of incubation time with TGF-b (1,
2, or 3 days) on fold change in the expression of the three
molecules of interest relative to their vehicle-treated levels
revealed a signiﬁcant effect of time, with the effect being
strongest for a-SMA expression (F2,23 Z 12.946,
P < 0.0005), followed by FN expression (F2,23 Z 7.095,
P Z 0.004) and weakest for COL1 (F2,23 Z 3.676,
PZ 0.041). Thus, with respect to intracellular expression of
a-SMA, COL1, and FN, we observed differences in the
magnitude and, especially for COL1, in the duration of in-
duction in cat corneal ﬁbroblasts after stimulation with TGF-
b1 under our culture conditions (Figure 4, AeD).
All three PPARg ligands signiﬁcantly decreased TGF-
b1einduced expression of a-SMA, COL1, and FN at all time
points examined. However, because a larger induction of
these three molecules was obtained in corneal ﬁbroblasts
after 2 to 3 days of stimulation with TGF-b1, the effect of the
PPARg ligands was much clearer at these later time points
(Figures 1, 2, 3, and 4). Furthermore, as shown in Figures 1,
2, and 3, the inhibitory effects of the three PPARg ligands
tested were clearly dose dependent, and when normalized to
the maximal levels of a-SMA, COL1, and FN induced by
TGF-b, the three compounds also showed some interesting
differences in the effect on a-SMA versus COL1 and FNajp.amjpathol.org - The American Journal of Pathology
Figure 2 Antiﬁbrotic effects of rosiglitazone on feline corneal ﬁbro-
blasts. A: Representative Western blots showing protein levels for ﬁbro-
nectin (FN), collagen 1 (COL1), and a-SMA. b-tubulin was used as a loading
control. B: Plots of relative expression of FN, COL1, and a-SMA normalized
to densitometric values obtained in cells stimulated with 1 ng/mL of TGF-
b1 for each culture day sampled. Data are means  SD averaged for three
experiments. *P < 0.0125 (four comparisons), yP < 0.0167 (three com-
parisons) by Bonferroni-corrected Student’s t-test relative to the TGF-
b1eonly condition (df Z 4 for all tests).
Figure 3 Antiﬁbrotic effects of 15d-PGJ2 on feline corneal ﬁbroblasts.
A: Representative Western blots showing protein levels for ﬁbronectin (FN),
collagen 1 (COL1), and a-SMA. b-tubulin levels were assayed as a loading
control. B: Plots of relative expression of FN, COL1, and a-SMA normalized
to maximum densitometric values obtained in cells stimulated with 1 ng/
mL of TGF-b1 for each culture day sampled. Data are means  SD averaged
for three experiments. *P < 0.0125 (four comparisons), yP < 0.0167 by
Bonferroni-corrected Student’s t-test relative to the TGF-beonly condition
(df Z 4 for all tests).
PPARg Ligands and Corneal Fibroblastsexpression (Figure 4, BeE). We performed an analysis of
variance probing the effect of treatment (with the three
different PPARg ligands) on fold change in the expression of
the three molecules of interest relative to their vehicle-treated
levels to ascertain whether optimal doses of the three PPARg
ligands exerted essentially identical effects on these three
molecules of interest. For COL1 (F2,6Z 0.103, PZ 0.904)
and FN (F2,6Z 1.776, PZ 0.248), the three ligands behaved
similarly, but in the case of a-SMA, there were signiﬁcant
differences in the different ligands’ abilities to inhibit a-SMA
expression (F2,6Z 9.248, PZ 0.015).
As mentioned earlier, different ligands were most effec-
tive at different doses. With respect to TGF-b1einduced
a-SMA expression, after 2 days in culture, the lowest
effective doses were 15 mmol/L for troglitazone, 50 mmol/L
for rosiglitazone, and 1 mmol/L for 15d-PGJ2, which was
sufﬁcient to signiﬁcantly knock down a-SMA expressionThe American Journal of Pathology - ajp.amjpathol.org(5 mmol/L was the highest nontoxic dose). Similar results
were obtained after 3 days in culture. Basically, the elec-
trophilic PPARg ligand 15d-PGJ2 could decrease TGF-
b1einduced a-SMA expression at much lower doses (10- to
75-fold lower) than either of the two thiazolidinediones.
However, evenwhen used at the right dose, troglitazone and
15d-PGJ2 were able to decrease a-SMA levels back to base-
line levels of expression (0.8  0.2-fold above baseline
compared with 60  11-fold above baseline when incubated
with just TGF-b1 for 3 days). This represented an approxi-
mately 60-fold reduction in TGF-b1einduced a-SMA
expression as a result of treatment with these PPARg ligands.
In contrast, rosiglitazone decreased a-SMA levels to only
2  0.3-fold above baseline, still a 30-fold reduction relative
to the TGF-b1estimulated condition but nevertheless a
signiﬁcantly lesser effect than that exerted by troglitazone
(PZ 0.048, dfZ 4) and 15d-PGJ2 (PZ 0.019, dfZ 4).1435
Figure 4 Comparative effect of TGF-b and
PPARg ligands on expression of a-SMA, collagen 1
(COL1), and ﬁbronectin (FN) in feline corneal
ﬁbroblasts. A: Plot of change in expression of
a-SMA, COL1, and FN induced by TGF-b1 in
cultured cat corneal ﬁbroblasts for 1, 2, or 3 days
in culture relative to the control (vehicle-treated)
condition. BeD: Plots of the effect of the optimal
doses of the three PPARg ligands of interest on
expression of TGF-b1einduced a-SMA (B), TGF-b1e
induced COL1 (C), and TGF-b1einduced FN (D).
Changes in expression due to TGF-b alone (red in B,
blue in C, and green in D). E: Cultured cat corneal
ﬁbroblasts stained immunocytochemically for a-SMA
(red) and FN (green) and counterstained with DAPI
(blue) after 3 days in culture with the treatments
indicated in each image. Scale bars: 50 mm. Cont,
control; Tþ15d-PGJ2, TGF-b plus15d-PGJ2; TþRosi,
TGF-b plus rosiglitazone; TþTrog, TGF-b plus trogli-
tazone.
Jeon et alIn contrast, at the same three day time-point, and as
suggested by our earlier analysis of variance results, the
three PPARg ligands used here decreased levels of COL1
and FN to a similar extent and with no signiﬁcant differ-
ences in apparent effectiveness between ligands. For COL1,
they decreased expression from 11  3-fold above baseline
in the TGF-b1eonly condition to approximately 2  0.6-
fold above baselinedabout a ﬁvefold reduction. For FN,
PPARg ligand treatment decreased its expression from
approximately 25  6-fold above baseline in the TGF-
b1eonly condition to approximately 5  2.5-fold above
baseline (also about a ﬁvefold reduction).
Our observations can be summarized into four major
ﬁndings: i) a-SMA appeared to be induced at greater rela-
tive levels than both COL1 and FN after exposure to TGF-
b1, especially after 2 and 3 days in culture; ii) all three
PPARg ligands tested in the present experiments, whether
electrophilic or nonelectrophilic, were able to decrease
a-SMA induction at 2 and 3 days in culture; however, this1436occurred at different doses for the different compounds, and
a-SMA levels returned to baseline only if the cultures were
treated with either troglitazone or 15d-PGJ2 (not rosiglita-
zone); iii) all three ligands also decreased the induction of
COL1 and FN in addition to a-SMA, but the levels of COL1
and FN remaining after treatment were still two- to ﬁvefold
above baseline, no matter which ligand was used; and iv)
optimal doses of rosiglitazone and troglitazone were only
able to reduce COL1 levels after 2 and 3 days of culture and
FN levels only after 3 days in culture.
Antiﬁbrotic Effects of PPARg Ligands Are PPARg
Independent
Although PPARg is widely expressed in the feline cornea,
both in epithelial cells and stromal keratocytes (Supplemental
Figure S1), it was important to test whether the observed
antiﬁbrotic effects of troglitazone, rosiglitazone, and 15d-
PGJ2 in cultured feline corneal ﬁbroblasts were PPARgajp.amjpathol.org - The American Journal of Pathology
PPARg Ligands and Corneal Fibroblastsdependent or independent. We ﬁrst used a pharmacologic
approach, co-incubating the optimal doses of the PPARg
ligands of interest with GW9662. In feline orbital ﬁbroblasts,
a cell type that can easily be induced to produce fat in a
PPARg-dependent manner,29 GW9662 inhibited PPARg
ligandeinduced fat production at doses ranging from 0.5 to 2
mmol/L, with 1 to 2 mmol/L proving equally and maximally
effective (Supplemental Figure S2A). Although effective at
reducing fat synthesis in cat orbital ﬁbroblasts, 1 mmol/L
GW9662 was unable to prevent the down-regulation of a-
SMA, COL1, or FN expression induced by the three PPARg
ligands of interest in cultured cat corneal ﬁbroblasts (Figure 5,
A and B). In addition, 1 mmol/L GW9662 also did not inﬂu-
ence TGF-b1einduced expression ofa-SMA, COL1, and FN
(Figure 5, A and B) in these cells, suggesting that the anti-
ﬁbrotic actions of the electrophilic and nonelectrophilicThe American Journal of Pathology - ajp.amjpathol.orgPPARg ligands tested in feline corneal ﬁbroblasts likely
occurred via PPARg-independent mechanisms.
We used a genetic approach as another method to test
whether the antiﬁbrotic actions of PPARg ligands occur
independently of PPARg. PPARg activity was blocked
using a PPARg-DN-Lv construct. The PPARg-Lv construct
expresses a mutant PPARg (Flag tag-PPARg1 L466A/
E469A), which cannot activate transcription of PPARg
target genes and blocks activity of endogenous PPARg.31
To test whether PPARg-DN could inhibit feline adipo-
genesis and thus feline PPARg, GFP-Lv or PPARg-DN-Lv
were introduced into feline orbital ﬁbroblasts by Lv infection.
Infected cells were induced to differentiate into adipocytes
with a standard adipogenic cocktail.30 GFP-Lveinfected
cells readily formed adipocytes, whereas PPARg-DN-Lve
infected cells did not (Supplemental Figure S2B). TheseFigure 5 PPARg dependence of antiﬁbrotic
effects exhibited by PPARg ligands. A: Represen-
tative Western blots show protein levels for a-SMA,
type 1 collagen (COL1), and ﬁbronectin (FN).
b-tubulin was used as a loading control. B: Plots of
the relative expression of FN, COL1, and a-SMA
normalized to the maximal densitometric values
obtained in cells stimulated with 1 ng/mL of
TGF-b1 for 3 culture days. Data are means  SD
averaged for three experiments. C: Western blot
analysis of a-SMA, COL1, FN, b-tubulin (loading
control), and PPARg levels of GFP-Lve or PPARg-
DN-Lveinfected corneal ﬁbroblasts treated with
vehicle, PPARg ligands, and/or TGFb. PPARg-DN-
Lveinfected corneal ﬁbroblasts express high levels
of ﬂag-tagged PPARg-DN protein (upper band)
that blocks endogenous PPARg (lower band)
activity. **P < 0.01 by Bonferroni-corrected
Student’s t-test for rosiglitazone relative to the
TGF-b1eonly condition; yP < 0.0125 by
Bonferroni-corrected Student’s t-test for troglita-
zone and 15d-PGJ2 relative to the TGF-b1eonly
condition in each graph (df Z 4 for all tests).
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Figure 6 Effect of PPARg ligands on TGF-b1einduced phosphorylation
and nuclear translocation of Smads 2/3. A: Western blots show effect of rosi-
glitazone and troglitazone on TGF-b1einduced phosphorylation of Smad 2
protein. Total Smads 2/3 levels were assayed as a loading control. B: Pre-
incubation with 15 mmol/L of troglitazone does not appear to inhibit TGF-
b1einduced phosphorylation of Smad 3 or alter total levels of Smad 2/3. C:
Western blots show the effect of troglitazone on TGF-b1einduced nuclear
translocation of Smads 2/3. TGF-b1 increases the amount of phosphorylated
Smads (p-Smad) 2 and 3 in both the nuclear (NE) and cytoplasmic (CE) fractions
after the 1-hour incubationperiod (lanes 2 and6). Preincubationwith 15mmol/
L troglitazone before adding TGF-b1 does not alter the levels of p-Smads 2/3 or
total Smads 2/3 in either fraction (lanes 3 and 7). Because TGF-b1 treatment
moved p-Smads 2/3 into nucleus, the levels of total Smads 2/3 became uneven,
with a smaller amount left in the cytoplasmic fraction (compare lanes 1 and 2)
and a greater amount in the nucleus (compare lanes 5 and 6).
Figure 7 Effect of TGF-b1 stimulation on phosphorylation of non-Smad
signaling molecules in cat corneal ﬁbroblasts. Western blot shows the time
course of control (C) and TGF-b stimulation (T) on the expression of
phosphorylated p38 (p-p38) and total p38 (p38) in cultured cat corneal
ﬁbroblasts (A) and the effect of C and T on phosphorylated JNK (p-JNK),
phosphorylated ERK1/2 (p-ERK1/2), phosphorylated AKT (p-AKT), and
phosphorylated MLC2 (p-MLC2), with levels of b-tubulin assayed as a
loading control (B). m, minutes; hr, hours
Jeon et aldata revealed that PPARg-DN could indeed inhibit feline
PPARg.
We then infected feline corneal ﬁbroblasts with GFP or
PPARg-DN expressing Lv. Infected cells were treated with
optimal doses of PPARg ligands and TGF-b as described
above, and cell extracts were analyzed for myoﬁbroblast
markers and PPARg expression (Figure 5C). Expression of
PPARg-DN that blocks PPARg activity had no effect on the
ability of PPARg ligands to inhibit expression of myoﬁ-
broblast markers (a-SMA, COL1, and FN), conﬁrming the
pharmacologic results described above for GW9662 and
strongly suggesting that the antiﬁbrotic actions of PPARg
ligands likely occur independently of PPARg.
PPARg Ligands Do Not Affect TGF-b1eInduced
Phosphorylation and Nuclear Translocation of Smads 2/3
Consistent with previous studies in other species,32 expo-
sure of cultured feline corneal ﬁbroblasts to TGF-b1 for14381 hour resulted in a huge increase of phosphorylation of
Smads 2 and 3 (Figure 6, A and B). Longer incubation times
with TGF-b1 (up to 6 hours) saw levels of these phos-
phorylated proteins diminish relative to total Smads 2/3
(Figure 6, A and B). Preincubation with rosiglitazone and
troglitazone (Figure 6A) failed to inhibit TGF-b1einduced
phosphorylation of Smad 2 (Figure 6A) or Smad 3 for
troglitazone (Figure 6B) at all of the time points examined.
Total Smad 2/3 levels also remained unchanged (Figure 6,
A and B).
Another key possible site of action of PPARg ligands
with respect to Smad signaling is translocation of phos-
phorylated Smads 2/3 to the nucleus. Thus, we assayed the
relative amounts of phosphorylated Smads 2/3 in the cyto-
plasmic and nuclear fractions after a 1-hour incubation time
with TGF-b1. TGF-b1 increased the amount of phosphor-
ylated Smads 2 and 3 in both fractions after the 1-hour in-
cubation period (Figure 6C). Pre-incubation of the cells with
troglitazone before adding TGF-b1 did not alter the levels of
phosphorylated Smads 2/3 or total Smads 2/3 in either
fraction (Figure 6C). Finally, neither the vehicle (Figure 6C)ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Effect of kinase inhibitors on TGF-b1einduced expression of a-SMA, collagen 1 (COL1), and ﬁbronectin (FN). A: Model of the multiple signaling
molecules and pathways activated by TGF-b binding to its receptor. The different kinase inhibitors used are indicated in red and positioned close to their
putative site of action. B: Representative Western blots show the effect of the TGF-b receptor 1 inhibitor SB431542 (as a positive control) on TGF-b1einduced
expression of a-SMA, COL1, and FN in cultured corneal ﬁbroblasts. Used concentrations are indicated above each blot. C: Western blots showing effect of
different inhibitors on TGF-b1einduced expression of a-SMA, COL1, and FN in cultured corneal ﬁbroblasts. We used the Rho-kinase inhibitor H-1152, the ERK
inhibitor U0126, the p38 inhibitor SB203580, the AKT inhibitor LY294002. Red X, indicates two different JNK inhibitors (SP600125 and JNK inhibitor III).
Concentrations of each inhibitor used are shown above each blot.
PPARg Ligands and Corneal Fibroblastsnor troglitazone alone (Figure 6C) inﬂuenced phosphory-
lation of Smads 2/3 or their translocation into the nucleus.
Thus, it seems that the antiﬁbrotic actions of PPARg ligands
in corneal ﬁbroblasts did not occur by blocking either TGF-
b1emediated phosphorylation or nuclear translocation of
Smads 2/3 during the ﬁrst 6 hours after treatment.
Effect of TGF-b1 Stimulation on Phosphorylation of
Downstream Signaling Molecules
Accumulating evidence suggests that tetrameric TGF-b re-
ceptor complexes activate a number of Smad-independent
signaling pathways, which may also play a role in gener-
ating ﬁbrotic phenotypes in a range of body tissues.9 Our
goals were to identify which of these signaling pathways
were most strongly activated by TGF-b in cat corneal ﬁ-
broblasts under our particular cell culture conditions and to
assess whether these pathways were inﬂuenced by optimal
doses of PPARg ligands, offering a possible substrate for
their antiﬁbrotic actions. We ﬁrst assayed which of the main
non-Smad signaling molecules were increased by incubationThe American Journal of Pathology - ajp.amjpathol.orgwith TGF-b1 and over what time frame. As summarized in
Figure 7A, the activation of p38 MAPK (in the form of
increased levels of phosphorylated p38 relative to total p38)
appeared to be the most signiﬁcant change observed,
starting within minutes after TGF-b1 stimulation and per-
sisting for at least 24 hours. Phosphorylation of MLC2,
indicative of ROCK activation, was also observed on in-
cubation with TGF-b1 at 1 hour, but the effect disappeared
thereafter (Figure 7B). In contrast, there were no TGF-b1e
induced increases in levels of phosphorylated AKT, phos-
phorylated ERK1/2, and phosphorylated JNK compared
with DMSO-treated vehicle at any of the time points
examined (Figure 7B).
Effect of Kinase Inhibitors on TGF-b1eInduced
Expression of a-SMA, COL1, and FN
To critically test whether phosphorylation of p38 was a key
signal for translating TGF-b receptor binding into a
myoﬁbroblastic phenotype in corneal ﬁbroblasts, we used
small-molecule inhibitors (Figure 8A) to block endogenous1439
Figure 9 Effect of PPARg ligands on TGF-b1einduced phosphorylation of p38 MAPK signaling in cultured corneal ﬁbroblasts. Representative Western blots
show the stimulatory effect of TGF-b1 on levels of phosphorylated p38 (p-p38) and the inhibitory actions of troglitazone (troglit.), 15d-PGJ2, and rosigli-
tazone (rosi.) on levels of p-p38. The three bar plots show the means  SD of densitometric measures (speciﬁcally, the ratio of p-p38 to p38 for each
treatment condition, normalized to the ratio obtained after TGF-b treatment alone) averaged for three separate experiments. *P < 0.0167 by Bonferroni-
corrected Student’s t-test relative to the TGF-b1eonly condition (df Z 4 for all tests).
Jeon et alprotein kinases responsible for phosphorylation in each of
the signaling pathways examined earlier. We then assessed
consequences of this inhibition on the expression of
a-SMA, COL1, and FN after TGF-b1 stimulation. As ex-
pected, the TGF-b receptor 1 inhibitor (SB431542) elimi-
nated TGF-b1einduced increases in a-SMA and FN
expression at 1 ng/mL (Figure 8B); it also returned COL1
expression to basal levels at a slightly higher dose of
5 ng/mL (not shown). The other kinase inhibitors used also
diminished a-SMA expression in a concentration-dependent
manner (Figure 8C). The p38 kinase inhibitor (SB203580)
andRho-kinase inhibitor (H-1152)were almost as effective as
the TGF-b receptor 1 inhibitor at concurrently blocking both
the TGF-b1einduced increases in a-SMA, COL1, and FN
expression, with a slight advantage exhibited by SB203580 at
a dose of 4 to 5 mmol/L (Figure 8C). Other inhibitors (eg, the
two JNK and the Akt kinase inhibitors) appeared to exert a
stronger effect on a-SMA expression and a weaker effect on
COL1 and FN expression (Figure 8C). The most extreme
example of this was seen with the ERK kinase inhibitor,
U0126 (Figure 8C), which prevented increases in a-SMA
expression but failed to alter COL1 and FN expression, even
at the highest dose (10 mmol/L) tested. Thus, in cat corneal
ﬁbroblasts, as in ﬁbroblasts from other parts of the body, the
tetrameric TGF-b receptor complex activated multiple intra-
cellular pathways to induce the expression of proﬁbrotic
molecules. Although all of the pathways tested here inﬂu-
enced a-SMA expression to some extent, only a subset of
these pathways also regulated expression of FN and COL1 at
the same doses. Even for pathways that appeared to regulate
COL1 and FN expression, higher doses of kinase inhibitors
were usually required to exert the level of inhibition seen for
a-SMA expression. The major exception was phosphoryla-
tion of p38 MAPK, whose inhibition appeared the most1440effective at blocking TGF-b1einduced increases in all three
proﬁbrotic molecules of interest at similar doses of the rele-
vant kinase inhibitor.
PPARg Ligands Decrease TGF-b1eInduced
Phosphorylation of p38 MAPK
These experiments showed that among multiple signaling
molecules that could mediate myoﬁbroblast differentiation,
p38 MAPK phosphorylation i) was reliably activated by
TGF-b1 stimulation, ii) persisted for at least 24 hours after
TGF-b1 stimulation, and iii) was inhibited by SB203580,
which simultaneously prevented TGF-b1einduced in-
creases in a-SMA, COL1, and FN expression. Our next
question in this context was whether the PPARg ligands of
interest blocked TGF-b1einduced increases in a-SMA,
COL1, and FN expression by decreasing phosphorylation of
p38 MAPK in cultured corneal ﬁbroblasts. As shown in
Figure 9, troglitazone, rosiglitazone, and 15d-PGJ2 all
decreased the levels of phosphorylated p38 MAPK induced
by incubation with TGF-b1 in a dose-dependent manner.
Importantly, the doses of these three drugs that were
effective at decreasing levels of a-SMA, COL1, and FN
expression (Figures 1, 2, and 3) were similarly effective at
decreasing phosphorylated p38 MAPK expression
(Figure 9). In contrast, total p38 MAPK levels were unaf-
fected by addition of these three PPARg ligands (Figure 9).
Troglitazone Is a Potent Antiﬁbrotic during Corneal
Wound Healing in Vivo
Finally, in an attempt to assess whether small molecule
synthetic PPARg ligands are able to curtail ﬁbrosis after
corneal wounding in vivo, we applied troglitazone topicallyajp.amjpathol.org - The American Journal of Pathology
Figure 10 Antiﬁbrotic effects of troglitazone
in vivo. A: Photographs of four cat eyes who un-
derwent conventional PRK with 10-Diopter
ablation in a 6-mm optical zone. PRK was fol-
lowed by topical application of either vehicle so-
lution (10% DMSO in Celluvisc) or three different
doses of troglitazone (troglit.) diluted in 10%
DMSO/Celluvisc. Visual inspection of the cat eyes
at different time points after PRK reveals a clear
dose response in the effect of topical troglitazone
relative to the vehicle solution. Note toxic reaction
to 100 mmol/L troglitazone. B: OCT images of the
cat eyes in A collected 3 weeks after operation.
OCT imaging conﬁrms the appearance of a band of
increased stromal reﬂectivity at the ablation zone
(arrow), which signiﬁcantly decreases in eyes
treated with 10 mmol/L troglitazone. C: Graphs of
normalized intensity change in the anterior 30% of
the stroma relative to preoperative values (zero),
measured from OCT images such as those in B, and
plotted separately for vehicle-treated (DMSO/Cel-
luvisc) corneas (white symbols) or corneas that
received 10 mmol/L troglitazone after PRK (black
symbols). D: Graphs of normalized intensity
change in the posterior 30% of the stroma relative
to preoperative values (zero), measured from OCT
images such as those in B, and plotted separately
for vehicle-treated (DMSO/Celluvisc) corneas (white
symbols) or corneas that received 10 mmol/L tro-
glitazone after PRK (black symbols). Error bars
indicate SEM (C and D). wks, weeks.
PPARg Ligands and Corneal Fibroblaststo live cat eyes after PRK. PRK involves epithelial
debridement and laser ablation of the stromal bed to a depth
of approximately 160 mm; it normally induces a strong
wound healing reaction in the cat.7,19,39 Visual inspection of
the clarity of the cat corneas at different time points after
PRK revealed a clear dose response in the effect of trogli-
tazone relative to application of the vehicle solution alone
(Figure 10A): 1 mmol/L troglitazone caused little reduction
of haze relative to the application of vehicle solution after
PRK. Application of 100 mmol/L troglitazone at the same
rate caused overt corneal toxicity, evidenced by prolonged
opaciﬁcation and swelling of the cornea. Application of 10
mmol/L troglitazone resulted in better corneal clarity at early
time points after PRK relative to vehicle-treated eyes. These
ﬁndings were veriﬁed by OCT imaging (Figure 10, BeD)
and histologic analysis (Figure 11). OCT imaging conﬁrmed
the appearance of a band of increased reﬂectivity occurring
at the stromal ablation zone (Figure 10B). This band was
thickest (ie, extending to the greatest depth into the cornea)The American Journal of Pathology - ajp.amjpathol.orgin eyes receiving vehicle solution and 1 mmol/L troglitazone
after PRK. The band of increased reﬂectivity was thinnest in
the eyes treated with 10 mmol/L troglitazone after PRK.
Eyes treated with 100 mmol/L troglitazone exhibited a
pathologic corneal appearance on OCT, with signiﬁcant
swelling, increased reﬂectivity throughout the entire depth
of the cornea, and the inability to clearly deﬁne an epithelial
layer (Figure 10B).
At 2weeks after PRK, quantitative analysis of OCT images
in 10 cats showed that the backscatter reﬂectivity of the
anterior 30% of the stroma of vehicle-treated eyes was
increased by means  SEM of 61%  5% relative to preop-
erative levels. In contrast, eyes treated with 10 mmol/L tro-
glitazone exhibited an increase of only 39%  6% at the end
of treatment, a statistically signiﬁcant difference (PZ0.0149,
Student’s t-test, df Z 18). By 4 weeks after PRK, 2 weeks
after the end of treatment, backscatter reﬂectivity of the
anterior 30% of the stroma was still 52%  8% higher than
preoperatively in vehicle-treated eyes. In troglitazone-treated1441
Figure 11 Immunostaining for a-SMA (green)
in cat corneal sections counterstained with pro-
pidium iodide (PI-red) of postmortem cat corneas.
No a-SMA staining is observed in unoperated on
corneas. Note the strongly stained, continuous
band of a-SMAepositive cells in the stroma adja-
cent to the ablation zone at both 2 and 4 weeks
after PRK in vehicle-treated eyes. In contrast,
there is a signiﬁcant reduction in a-SMA expres-
sion in the corneas treated with 10 mm troglita-
zone and examined at both 2 and 4 weeks after
PRK.
Jeon et aleyes, this value was approximately half, at 27% 7%, also a
statistically signiﬁcant difference (P Z 0.043, Student’s t-
test, df Z 14). By 12 weeks postoperatively, backscatter
reﬂectivity in vehicle-treated eyes was only 11%  2.5%
greater than preoperative levels, whereas in troglitazone-
treated eyes, it was 10%  3.0% greater, values that were
no longer signiﬁcantly different from each other (Figure 10C).
A two-way analysis of variance was conducted to examine
the effect of postoperative treatment (10 mmol/L troglitazone
or vehicle) and time (2, 4, 8, and 12 weeks after PRK) on
change in backscatter reﬂectivity in the anterior 30% of the
stroma. There were signiﬁcant main effects of treatment
(F1,44 Z 6.605, P Z 0.014) and time (F3,44 Z 14.891,
P < 0.0005) on reﬂectivity but no signiﬁcant interaction be-
tween the two (F3,44Z 1.235, PZ 0.308). A similar result
was obtained for backscatter reﬂectivity in the posterior 30%
of the stroma (Figure 10D). There was a signiﬁcant main ef-
fect of treatment (F1,44 Z 6.562, P Z 0.014) and time
(F3,44Z 4.442, PZ 0.008) on reﬂectivity but no signiﬁcant
interaction between the two (F3,44Z 0.225, PZ 0.878). The
posterior stromal reﬂectivity was increased signiﬁcantly
above preoperative levels up to 8 weeks after PRK in vehicle-
treated eyes (Figure 10D). In contrast, troglitazone-treated
eyes (Figure 10D) exhibited half the increase seen in
vehicle-treated eyes at 2 weeks after PRK, and by 4 weeks
after PRK, intensity levels had decreased enough that they
were no longer signiﬁcantly higher than preoperatively.
Immunoﬂuorescent staining of corneas from the different
treatment groups post mortem revealed a strongly stained,
continuous band of a-SMAepositive cells in the anterior
stroma of the ablation zone at both 2 and 4 weeks after PRK
in vehicle-treated eyes (Figure 11). In contrast, 10 mmol/L
of troglitazone applied topically every day for 2 weeks
postoperatively signiﬁcantly inhibited the development of
this a-SMAepositive zone at both 2 and 4 weeks after PRK.
Only a few, dispersed clusters of a-SMAepositive cells were
seen under the epithelium at both time points (Figure 11). This
result indicates that the antiﬁbrotic actions of PPARg ligands
reported above in cultured feline cornealﬁbroblasts also apply1442in vivo, when such compounds are used topically in live cat
eyes after corneal wounding.Discussion
Corneal scarring is a predominant afﬂiction worldwide. It
has no effective treatment without adverse effects and when
untreated can cause blindness.42 Finding a safe way of
controlling corneal scarring and ﬁbrosis would be of
tremendous public health beneﬁt.
Recently, we reported on the beneﬁcial optical and bio-
logical consequences of using rosiglitazone, a synthetic
PPARg ligand, topically in cat eyes to control ﬁbrosis after
PRK.19 However, we do not know how rosiglitazone exerts
its antiﬁbrotic actions in the cornea or whether it is unique
among PPARg ligands in being able to act this way.
Moreover, the successful application of rosiglitazone to treat
corneal ﬁbrosis in vivo seemed to run counter to its weak
effects in a prior in vitro study using human corneal ﬁbro-
blasts.16 Thus, we characterized the mechanisms of anti-
ﬁbrotic action of rosiglitazone and two other PPARg
ligands in feline corneal ﬁbroblasts in vitro. We found these
cells to behave similarly in culture compared with corneal
ﬁbroblasts from rabbits,43 cows,25 and humans.44
TGF-b1 stimulation caused cat corneal ﬁbroblasts to ex-
press a-SMA, COL1, and FN at increasing levels during
consecutive days, just as it did in corneal ﬁbroblasts from
other species.25,43,44 Both electrophilic (15d-PGJ2) and
nonelectrophilic (rosiglitazone and troglitazone) PPARg
ligands almost completely blocked the TGF-beinduced in-
creases in a-SMA expression. These drugs also signiﬁcantly
reduced increases in the intracellular expression of COL1 and
FN, although never back to baseline levels. Notably, the
doses of 15d-PGJ2 needed to exert these effects (2.5 to 5
mmol/L) were much lower than the doses of troglitazone (10
to 15 mmol/L) and rosiglitazone (50 to 75 mmol/L). Thus, our
results conﬁrm and may even explain data from prior in vitro
studies that reported lack of effectiveness of rosiglitazone inajp.amjpathol.org - The American Journal of Pathology
PPARg Ligands and Corneal Fibroblastshuman corneal ﬁbroblasts but only used this drug at a
maximal dose of 10 mmol/L.16 We found this dose to be
relatively ineffective at decreasing myoﬁbroblast trans-
formation in cat corneal cells.
Prior work in a variety of tissues suggested that the anti-
ﬁbrotic actions of PPARg ligands occurred via a combination
of PPARg-dependent and -independent mechanisms.23,45,46
In cultured rabbit corneal ﬁbroblasts, Pan et al18 came to the
same conclusion with respect to pioglitazone’s antiﬁbrotic
actions. However, in human corneal ﬁbroblasts, Kuriyan
et al16 found that the antiﬁbrotic effects ofCDDO-Meand15d-
PGJ2 were largely PPARg independent. In the present ex-
periments, we used both a pharmacologic47 and a DN genetic
approach16,31 to block PPARg in vitro.We ﬁrst veriﬁed that in
feline orbital ﬁbroblasts, as in those from other species,48
PPARg ligands were able to increase fat production in a
PPARg-dependent manner. We then found that neither phar-
macologic nor genetic blockade of PPARg function were able
to prevent, even partially, the antiﬁbrotic effects of the three
PPARg ligands of interest in cat corneal ﬁbroblasts. Why our
ﬁndings differ from those of Pan et al18 remains a matter of
speculation. Differences in cell culture conditions, treatment
times (3 days in the present study versus 1 day in theirs), and
the mechanisms of action of pioglitazone versus the PPARg
ligands tested here are among the possible explanations.
If PPARg ligands did not work via PPARg, a reasonable
next question was whether they might control corneal ﬁbrosis
by regulating Smads 2/3. As expected, we found that TGF-b1
increased the phosphorylation and nuclear translocation of
Smads 2/3 in cat corneal ﬁbroblasts. However, optimal doses
of our PPARg ligands of interest did not seem to inﬂuence
either process, prompting us to probe some of the other
signaling pathways activated by TGF-b stimulation,
including ERK1/2, p38 MAPK, JNK MAPK, Rho, and
AKT.9 We used small-molecule inhibitors to block key pro-
tein kinases responsible for phosphorylation in each pathway
and assessed whether these inhibitors prevented TGF-
b1einduced increases in the expression of a-SMA, COL1,
and FN. We observed i) equivalent blockage of a-SMA,
COL1, and FN expression (H-1152, SB203580, and
SB431542); ii) a stronger block on a-SMA and a weaker
block on COL1 and FN expression (SP600125, JNK inhibitor
III, LY294002); or iii) blockage of a-SMA but no effect
on COL1 and FN expression (U0126). Thus, the signaling
molecules downstream of TGF-b receptor activation
appeared to differentially regulate synthesis of a-SMA versus
extracellular matrix components in corneal ﬁbroblasts.
However, p38 MAPK was the only molecule i) whose
phosphorylation was reliably induced by TGF-b1 stimula-
tion, ii) for which the TGF-b1erelated induction persisted for
at least 24 hours, and iii) whose inhibition with SB203580
simultaneously prevented TGF-b1einduced increases in a-
SMA, COL1, and FN expression. Huh et al49 also reported
that p38 MAPK was an important TGF-beinduced interme-
diate in corneal ﬁbrotic wound repair and that it co-localized
with a-SMA in vivo. More recently, Yang et al50 reported thatThe American Journal of Pathology - ajp.amjpathol.orgamongMAPKs, p38MAPK activation by TGF-bwas critical
to sustain activation of Smad 2 for an extended period. This, in
turn, was necessary for myoﬁbroblast differentiation.
A ﬁnal piece of supporting evidence for the putative role
of p38 MAPK in mediating the antiﬁbrotic actions of
PPARg ligands in cultured, cat corneal ﬁbroblasts was that
doses of 15d-PGJ2, troglitazone, and rosiglitazone that were
optimal for blocking induction of a-SMA, COL1, and FN
also blocked the TGF-beinduced increase in phosphory-
lated p38 MAPK. In view of the work of Yang et al,50 we
hypothesize that PPARg ligands, by blocking TGF-
beinduced p38 MAPK activation, should decrease Smad 2
activation at late time points rather than the early time points
(Figure 6) after TGF-b stimulation.
With respect to in vivo testing, application of troglitazone
to the ocular surface after PRK decreased stromal a-SMA
expression at 2 and 4 weeks postoperatively, consistent with
our previous results with rosiglitazone in this animal model.19
OCT imaging at these time points revealed troglitazone to
also decrease the size and intensity of the band of high
backscatter reﬂectivity normally induced by PRK in the
ablation zone stroma. There was a clear dose response for the
effects of troglitazone in cat eyes, with doses 10 lower than
the optimal exerting little visible effect and doses 10 higher
than the optimal exerting a toxic effect. The cause of the
toxicity remains to be determined, but we posit that it may
involve endothelial failure, which would explain the
observed corneal swelling and opaciﬁcation. In summary,
rosiglitazone is not unique among PPARg ligands for
exerting antiﬁbrotic effects in the cornea in vivo. Troglitazone
exerts a similar effect, and it is likely that other PPARg li-
gands may also be good candidates as antiscarring medica-
tions for the cornea. However, given their different effective
doses in vitro and the signiﬁcant consequences of toxicity in
the cornea, it seems prudent that careful dose-response de-
terminations be made separately for each drug in vivo.
In conclusion, the present results reveal several different
PPARg ligands to be effective corneal antiﬁbrotics in vitro
and in vivo. Electrophilic ligands appear to be more
effective at lower doses than nonelectrophilic ligands. All
three PPARg ligands tested appeared to function via
PPARg- and early Smad 2/3eindependent signaling.
Instead, they altered phosphorylation of p38 MAPK.
Future studies should elucidate downstream and upstream
components of the p38 pathway affected by PPARg li-
gands and the effect of these small molecules on the other
critical, cellular components of the corneadthe epithelial
and endothelial cell layers. Nevertheless, our ﬁndings
suggest that PPARg ligands may be a promising class of
antiﬁbrotic drugs for corneal applications.Acknowledgments
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